Nanobiotix S.A. Stock Price, News & Analysis

NANOBIOTIX (NASDAQ: NBTX) announced a virtual KOL event on June 11, 2021, at 8 AM ET, targeting analysts, investors, and the scientific community. The event will showcase key opinion leaders discussing the immunotherapy data from the 2021 ASCO Annual Meeting and the first-in-class radioenhancer NBTXR3's role in oncology. Highlights include presentations on NBTXR3's mode of action, safety and efficacy updates, and its potential as a combination-agnostic product. Registration for the event is open, and the webcast will be available for later viewing.

Nanobiotix (NASDAQ: NBTX) announced updated data on its immunotherapy product NBTXR3 at the 2021 ASCO Meeting. The data shows promising results in treating advanced cancer patients with NBTXR3 combined with radiotherapy and anti-PD-1 therapy. Out of 13 evaluable patients, 76.9% demonstrated tumor regression. Notably, 80% of anti-PD-1 naïve patients had tumor regression, and 75% of previously resistant patients showed tumor regression. The study supports NBTXR3's potential to enhance immune responses against cancer, addressing significant unmet needs in immunotherapy.

Nanobiotix (NASDAQ: NBTX) has appointed Bart Van Rhijn as the new CFO, succeeding Philippe Mauberna, who served for eight years. Van Rhijn comes with a strong background in financial management and business development, particularly in the pharmaceutical sector. His leadership is expected to facilitate the launch of the company’s second clinical registration study for NBTXR3 in head and neck cancer and to support expansion in immunotherapy and other solid tumor therapies. Mauberna will remain temporarily to assist during this transition.

NANOBIOTIX (NASDAQ: NBTX), a late-stage biotechnology company, announced that CEO Laurent Levy will present the company's latest developments at the Jefferies Virtual Healthcare Conference on June 4 at 8:00 AM ET (14:00 CET). The event will be available via a live webcast and an archived recording on the company’s website. Nanobiotix focuses on innovative physics-based treatments for cancer and is known for its lead candidate NBTXR3, which has received market authorization in Europe for treating soft tissue sarcoma under the brand name Hensify®.

Nanobiotix (NASDAQ: NBTX) announced the appointment of Dr. Gary Phillips as the new chairman of its supervisory board, succeeding Laurent Condomine. Dr. Phillips brings extensive experience from his roles at OrphoMed and Mallinckrodt Pharmaceuticals. His appointment coincides with the company's strategic focus on advancing its development programs, particularly in head and neck cancer and immunotherapy. Condomine, who led the board for 11 years, oversaw significant milestones, including the launch of NBTXR3, which has received European market authorization. This leadership transition is expected to enhance Nanobiotix's growth trajectory.

Nanobiotix (NASDAQ: NBTX) announced updates at the 2021 ASCO Annual Meeting regarding its leading oncology product NBTXR3 for treating head and neck cancer and advanced cancers. The data shows NBTXR3's potential to enhance the effectiveness of radiotherapy and immunotherapy. In a phase I study, patients with locally advanced head and neck squamous cell carcinoma exhibited an 82.5% objective response rate. The company is set to launch a pivotal phase III trial for NBTXR3 in 2021. Positive long-term safety data from a soft tissue sarcoma study was also reported.

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) announced that CEO Laurent Levy will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 7:00 AM ET. A live webcast will be available on their website, with a replay to follow. The company, founded in 2003 and headquartered in Paris, focuses on physics-based approaches to cancer treatment. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand Hensify®.

Nanobiotix (NASDAQ: NBTX) announces a partnership with LianBio to develop NBTXR3, a new cancer treatment, in Greater China and other Asian markets. LianBio will handle commercial development, with Nanobiotix receiving a $20 million upfront payment and potential milestone payments totaling up to $220 million. The collaboration includes participation in a Phase III study for head and neck cancer. NBTXR3 has shown promise in treating solid tumors and has received Fast Track designation from the FDA for certain patient groups.